Agara Reddy, MD
Psychiatry · Columbia, MONPI 1588752364
Payments from drug & device makers
Across 703 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Alkermes, Inc.$1K
- Lundbeck LLC$790
- AbbVie$761
- Takeda Pharmaceuticals U.S.A., Inc.$697
- plus $6K from 27 others
What the payments were for
- Food & beverage$11,73899%
- Education$1371%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson(2 entities) | 90 | $1,712 |
| Otsuka America Pharmaceutical, Inc. | 82 | $1,209 |
| Alkermes, Inc. | 67 | $1,192 |
| Lundbeck LLC | 55 | $790 |
| AbbVie(2 entities) | 55 | $761 |
| Takeda Pharmaceuticals U.S.A., Inc. | 39 | $697 |
| Validus Pharmaceuticals LLC | 15 | $605 |
| Sunovion Pharmaceuticals Inc. | 47 | $592 |
| Vanda Pharmaceuticals Inc. | 32 | $566 |
| Axsome Therapeutics, Inc. | 24 | $563 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 34 | $525 |
| Teva Pharmaceuticals USA, Inc. | 18 | $417 |
| Neurocrine Biosciences, Inc. | 31 | $376 |
| Corium, LLC | 14 | $253 |
| Supernus Pharmaceuticals, Inc. | 16 | $228 |
| Noven Therapeutics, LLC | 9 | $163 |
| E.r. Squibb & Sons, L.L.C. | 8 | $155 |
| Orexo US, Inc. | 10 | $151 |
| Collegium Pharmaceutical, Inc. | 9 | $147 |
| Avanir Pharmaceuticals, Inc. | 8 | $123 |
| Shire North American Group Inc | 9 | $122 |
| Eisai Inc. | 6 | $110 |
| Indivior Inc. | 6 | $100 |
| Arbor Pharmaceuticals, Inc. | 5 | $75 |
| Ironshore Pharmaceuticals Inc. | 4 | $69 |
| Boston Scientific | 1 | $32 |
| Jazz Pharmaceuticals Inc. | 2 | $31 |
| Merck | 2 | $27 |
| Neurelis, Inc. | 1 | $19 |
| Abbott | 1 | $19 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $18 |
| Sage Therapeutics, LLC | 1 | $17 |
| Neos Therapeutics, LP | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$428
- Equetro$363
- INVEGA SUSTENNA$250
- INVEGA TRINZA$250
- INVEGA$250
- SPRAVATO$250
- Auvelity$102
How this compares
$11,874 in reported general payments places this provider in the 90th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 77 | $325,376 |
| RexultiBrexpiprazole | 15 | $26,609 |
| Paliperidone ErPaliperidone | 72 | $14,902 |
| TrintellixVortioxetine Hydrobromide | 18 | $13,300 |
| Aripiprazole | 176 | $7,867 |
| JardianceEmpagliflozin | 12 | $7,237 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 178 | $7,017 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $6,817 |
| Lisdexamfetamine Dimesylate | 28 | $6,662 |
| Lurasidone Hcl | 61 | $6,590 |
| Quetiapine Fumarate | 353 | $5,897 |
| Chlorpromazine Hcl | 37 | $5,777 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 35 | $5,430 |
| Duloxetine Hcl | 214 | $5,068 |
| Bupropion XlBupropion Hcl | 204 | $4,687 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $1,712 | $325,37677 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,209 | $26,60915 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $697 | $20,11731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 680 psychiatry providers in Missouri.
Other psychiatry in Columbia
- Ganesh GopalakrishnaColumbia$1.3M
- Muaid IthmanColumbia$357K
- David BeckColumbia$80K
- Joseph ParksColumbia$63K
- Gregory MattingleySaint Charles$8.2M
- Junaid SyedSaint Louis$8M
- Eric CarbonellFestus$5.4M
- Ricky MofsenSaint Louis$4.9M
- Charles ConwaySaint Louis$3.8M
- Mohd MalikSaint Louis$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.